SITC 2022

Presentations

SGN-BB228 | Preclinical | Abstract #1201

SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin® bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells